VEGFA and neoplasm: In accordance with this paradox, it may be more beneficial to treat early tumors with anti-angiogenic drugs that inhibit tumor vascularization, rather than to treat highly vascularized, late-stage tumors, but research on early-stage anti-VEGF treatments is currently limited.